Novartis to test Intec's Accordion controlled-release delivery tech

By Gareth Macdonald contact

- Last updated on GMT

Gettyimages/futureimage
Gettyimages/futureimage

Related tags: Pharmacology

Novartis will trial a controlled release technology – dubbed the Accordion Pill – under an agreement with developer Intec Pharma Ltd.

The Swiss drug manufacturer will examine what impact the technology has on the pharmacokinetics (PK) of an unspecified compound in a Phase I study according to Intec. Further details of the project were not provided.

Intec CEO, Jeffrey Meckler, welcomed the deal, explaining "We are delighted to work with Novartis in potentially utilizing our Accordion Pill platform technology​."

He added that, “we hope to increase the number of partners who ask us to formulate Accordion Pills for their proprietary compounds."

News of the agreement – financial terms of which were not disclosed – comes weeks after Intec announced it had granted a Canadian patent for the Accordion technology.

The patent​ covers the technology in combination with Carbidopa and Levodopa (AP-CD/LD) – currently in a Phase III trial for advanced Parkinson’s disease – until April 2029.

Jerusalem-based Intec has similar patents in the US, Europe, China, Japan, South Korea, Hong Kong, South Africa, and Israel.

Background

The Accordion Pill technology fits inside a standard size capsule, and is composed of a multi-layer, planar structure, reminiscent of an accordion.

According to Intec, when the capsule reaches the stomach, the capsule unfolds, and the accordion structure made of pharmaceutical biodegradable polymeric films, dissolves.

The structure remains in the stomach for up to 12 hours said the firm, allowing it to release the drug into the upper gastrointestinal tract in a controlled manner.  

Related topics: Drug Delivery, Delivery technologies

Related news

Related products

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Fill Release at the Right Time in the Right Place

Fill Release at the Right Time in the Right Place

Gelita AG | 19-Sep-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers

Follow us

Products

View more

Webinars